ClinicalTrials.gg
Not yet recruitingNCT06644339DIALOGUpdated Oct 16, 2024

Remote Multichannel Monitoring of Patients With Chronic DIseAses Using Speech technoLogies Based On Artificial intelliGence

An interventional study of Voice assistant in Heart Failure, Diabetes Mellitus and Arterial Hypertension, sponsored by I.M. Sechenov First Moscow State Medical University. Not yet recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by I.M. Sechenov First Moscow State Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Heart Failure by I.M. Sechenov First Moscow State Medical University — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · I.M. Sechenov First Moscow State Medical University.

Started
2024
the only one that year
No phase
2 of 10
1 open now
Registered
7th of 10
by date

Among the 10 studies in Heart Failure by I.M. Sechenov First Moscow State Medical University, this one is the only one that started in 2024, is one of 2 with no phase, and was the 7th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 10 studies in Heart Failure by I.M. Sechenov First Moscow State Medical University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Failure by I.M. Sechenov First Moscow State Medical University, or all of them as a file.
02

Study summary

DIALOG is a study to assess the efficacy and safety of remote patient monitoring using virtual operator voice technologies and a business intelligence (BI) system for timely detection, prevention of early complications, worsening of the condition, and other adverse events in patients who have been discharged from the hospital.

Read the detailed description

After ensuring that the patient\'s characteristics meet the inclusion and exclusion criteria and confirming the patient\'s ability to use the \"voice assistant\", as provided in the research protocol, patients who have completed the briefing will be able to use the voice assistant at home. During the month, robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system will be conducted for five groups of patients (CHF, DM, AH, LPD, and patients who underwent total knee replacement) who have been discharged from the hospital. The system developed allows for quick surveys, collection of data on patient conditions, and convenient transfer of this data to the physician. The physician will receive information on patient status in a graphical form using a traffic light system. In the event of any red flags, the physician will contact the patient for further discussion on treatment strategies. The study will evaluate the efficacy and safety of utilizing the \"voice assistant\" by assessing the achievement of target values for controlled parameters, evaluating patient satisfaction and adherence to treatment, reducing the number of repeat hospitalization, and reducing overall mortality and cardiovascular-related mortality.

03

Conditions studied

  • Heart Failure
  • Diabetes Mellitus
  • Arterial Hypertension
  • Lymphoproliferative Disease
  • Total Knee Replacement

Keywords

  • heart failure
  • diabetes mellitus
  • arterial hypertension
  • lymphoproliferative diseases
  • knee replacement
  • remote monitoring
  • mHealth
  • telemedicine
  • voice assistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Disease diagnosed according to the latest Clinical practice guidelines
  • Stable condition at the time of discharge from the hospital
  • Written to participate in the study

Non-inclusion criteria:

  • Diagnosed dementia or severe cognitive impairment
  • The inability to use automatic devices to register blood pressure at home, a blood glucose meter
  • Alcohol or drug abuse
  • Inability to contact a voice assistant and other study requirements, due to major co-morbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and/or comply with the protocol instructions or follow-up procedures

Exclusion criteria

Exclusion Criteria:

  • Unwillingness of the patient to continue participating in the study
  • The development of conditions related to the criteria of non-inclusion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Heart Failure

    Patients with chronic heart failure who was hospitalized due to decompensation of their condition. Their condition should be stabilized before discharge. Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) related to heart failure.

    Device: Voice assistant

  • Experimental
    Diabetes mellitus

    Patients with diabetes mellitus who was hospitalized with unstable glucose level. Their condition should be stabilized before discharge. Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight, glucose) related to diabetes mellitus.

    Device: Voice assistant

  • Experimental
    Arterial hypertension

    Patients with arterial hypertension who was hospitalized with unstable arterial pressure. Their condition should be stabilized before discharge. Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, hypotension sings, signs of damage to target organs).

    Device: Voice assistant

  • Experimental
    Lymphoproliferative diseases

    Patients with any lymphoproliferative disease who is undergoing chemotherapy. Their condition should be stabilized before discharge. Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate) related to chemotherapy complications.

    Device: Voice assistant

  • Experimental
    Total knee replacement

    Patients who underwent total knee replacement. Their condition should be stabilized before discharge. Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands to automate data collection and obtain information about the patient's well-being and his vital signs (pain, fever) related to replacement complications.

    Device: Voice assistant

Interventions

  • DeviceVoice assistant

    Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands on the "question-answer" principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) depending on disease. Follow-up and management of disease provided by specialists at participating institutions.

06

What researchers measure

Primary outcomes

  1. cardiovascular mortality

    mortality rate

    Time frame: an average, 1 month after randomization

  2. all-cause mortality

    mortality rate

    Time frame: an average, 1 months after randomization

  3. complications, decompensations

    rate of complications and exacerbations of the main disease

    Time frame: an average, 1 month after randomization

Secondary outcomes

  1. achievement target or maximally tolerated doses

    achievement target or maximally tolerated doses for CHF, DM and AH

    Time frame: an average, 1 month after randomization

  2. satisfaction

    satisfaction of patients and doctors with the robotic speech questionnaire

    Time frame: an average, 1 month after randomization

  3. changes in medical adherence

    change in amount of taking drugs and doses

    Time frame: an average, 1 month after randomization

07

Study locations

1 site
  • Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), University Clinical Hospital No.1
    Moscow, 119048, Russian Federation
08

References and documents

Individual participant data

Plan to share: No — According to the Local Ethics Committee\'s rules, we are not allowed to provide this data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Feb 2025, 4 months later.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 4 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2024
First posted
Oct 16, 2024
StartEst.
Oct 15, 2024
Primary completionEst.
Feb 28, 2025
CompletionEst.
Apr 30, 2025
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06644339
Collaborators
PJSC VimpelCom
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Oct 15, 2024 (estimated)
Primary completion
Feb 28, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
Oct 16, 2024

Study contacts

Maria Kozhevnikova, Professor
Contact
kozhevnikova_m_v@staff.sechenov.ru
+79265605019
Aleksei Emelianov, Assistant
Contact
emelyanov_a_v@staff.sechenov.ru
+79998305785
Maria Kozhevnikova, Professor
principal investigator · The Sechenov First Moscow State Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion